Eckert & Ziegler SE (ETR: EUZ)
Market Cap | 929.29M |
Revenue (ttm) | 277.72M |
Net Income (ttm) | 29.39M |
Shares Out | 20.85M |
EPS (ttm) | 1.40 |
PE Ratio | 25.96 |
Forward PE | 24.94 |
Dividend | 0.05 (0.11%) |
Ex-Dividend Date | Oct 3, 2024 |
Volume | 38,678 |
Open | 43.72 |
Previous Close | 44.40 |
Day's Range | 43.36 - 44.84 |
52-Week Range | 32.74 - 50.05 |
Beta | 1.30 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 27, 2025 |
About Eckert & Ziegler SE
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynt... [Read more]
Financial Performance
In 2023, Eckert & Ziegler SE's revenue was 246.09 million, an increase of 10.74% compared to the previous year's 222.23 million. Earnings were 26.30 million, a decrease of -10.17%.
Financial StatementsNews
EQS-News: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW
EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Admission/Market Launch Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW 13.12.2024 / 09:00 CET/CEST The issue...
EQS-News: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
EQS-News: Eckert & Ziegler SE / Key word(s): Incoming Orders/Alliance Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics fo...
EQS-News: Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
EQS-News: Eckert & Ziegler SE / Key word(s): Product Launch Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply 02.12.2024 / 09:00 CET/CEST The issuer is solely res...
EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand - Lutetium-177 Chloride (n.c.a)
EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Approval/Market Launch Eckert & Ziegler Achieves European Approval for Theralugand - Lutetium-177 Chloride (n.c.a) 27.11.2024 / 09:00 CET/CEST T...
Eckert & Ziegler Boosts Financial Year Forecast Again!
Eckert & Ziegler SE has boosted its 2024 financial outlook, anticipating higher sales and EBIT. This Berlin-based company, listed on TecDAX and SDAX, credits strong 9-month results for the revision. J...
EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Change in Forecast Eckert & Ziegler raises its forecast for the current financial year once again 22-Nov-2024 / 15:27 CET/CEST Disclosure of an inside in...
EQS-Adhoc: Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225
EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 13-Nov-2024 / 08:54 CET/CEST Disclo...
Eckert & Ziegler Boosts Sales & Earnings in First 9 Months of 2023
Eckert & Ziegler SE has shown robust growth in 2024, with significant increases in sales and earnings, reinforcing their optimistic forecast for the year. Full details will be unveiled on November 14....
EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year
EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): 9 Month figures/Preliminary Results Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year 15-Oct-2024 / ...
EQS-News: Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
EQS-News: Eckert & Ziegler SE / Key word(s): Contract/Alliance Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply 08.10.2024 / 08:00 CET/CEST The issuer is solely responsible for th...
EQS-DD: Pentixapharm Holding AG: Dr. Hakim Bouterfa, Allocation of 3,800 spin-off shares in Pentixapharm Holding AG due to the ownership of 3,800 shares in Eckert & Ziegler SE.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...
EQS-DD: Pentixapharm Holding AG: Dr. Andreas Eckert, Allocation of 4 spin-off shares in Pentixapharm Holding AG due to the ownership of 4 shares in Eckert & Ziegler SE.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...
EQS-DD: Pentixapharm Holding AG: Dr. Harald Hasselmann, Allocation of 2,200 spin-off shares in Pentixapharm Holding AG due to the ownership of 2,200 shares in Eckert & Ziegler SE.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...
EQS-DD: Pentixapharm Holding AG: Jens Giltsch, Allocation of 761 spin-off shares in Pentixapharm Holding AG due to the ownership of 761 shares in Eckert & Ziegler SE.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...
EQS-News: Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register 02.10.2024 / 11:43 CET/CEST The issuer is solely respon...
EQS-News: Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange
EQS-News: Pentixapharm Holding AG / Key word(s): IPO Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange 12.09.2024 / 15:00 CE...
EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
EQS-News: Eckert & Ziegler SE / Key word(s): Expansion/Miscellaneous Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden 20.08.2024 / 17:00 CET/CEST The issuer i...
EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
EQS-News: Eckert & Ziegler SE / Key word(s): Contract/Alliance Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study 13.08.2024 / 09:00 CET/CES...
Eckert & Ziegler Sees Strong Sales and Earnings Surge in H1 2024
In the first half of 2024, our company saw remarkable growth, with sales surging by 23% to €145.4 million and net profit soaring by 65% to €18.0 million. The Medical and Isotope Products segments led ...
EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
EQS-News: Eckert & Ziegler SE / Key word(s): Half Year Report/Quarter Results Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024 09.08.2024 / 07:45 CET/CEST The issuer is s...